Clinical trials: Ovary Cancer
Fallopian Tube Clear Cell Adenocarcinoma, Ovarian Clear Cell Adenocarcinoma
Cabozantinib-S-Malate in Treating Patients With Recurrent or Progressive Ovarian, Fallopian Tube, or Primary Peritoneal Cancer
This phase II trial studies how well cabozantinib-s-malate works in treating patients with ovarian, fallopian tube, or primary peritoneal cavity cancer that has come back or is growing, spreading, or getting worse.
- Conditions
- Fallopian Tube Clear Cell Adenocarcinoma, Ovarian Clear Cell Adenocarcinoma, Recurrent Fallopian Tube Carcinoma, Recurrent Ovarian Carcinoma
- Trial name
- NCT02315430
- Testing
- Cabozantinib S-malate, Laboratory Biomarker Analysis
- Where
- 410 sites in United States
- Volunteers
- 13 people
- Sponsor
- National Cancer Institute (NCI)
Polycystic Ovary Syndrome
Effects of Pioglitazone on Insulin and Glucose Metabolism in Women With Polycystic Ovary Syndrome (PCOS)
Our hypothesis is that hyperinsulinemia increases the renal clearance of D-chiro-inositol (DCI) in women with polycystic ovary syndrome (PCOS) and that this leads to a reduction in circulating insulin-stimulated…
- Trial name
- PCOS (NCT00868140)
- Testing
- pioglitazone
- Where
- 2 sites in United States, Venezuela
- Volunteers
- 51 people
- Sponsor
- Virginia Commonwealth University
Recurrent Fallopian Tube Carcinoma, Recurrent Ovarian Carcinoma
Perfusion CT in Predicting Outcomes in Ovarian, Fallopian, or Peritoneal Cancer With Bevacizumab
This phase II trial studies how well computed tomography perfusion imaging works in predicting outcomes in patients with ovarian, fallopian tube, or primary peritoneal cancer who are receiving bevacizumab.
- Conditions
- Recurrent Fallopian Tube Carcinoma, Recurrent Ovarian Carcinoma, Recurrent Primary Peritoneal Carcinoma
- Trial name
- NCT03412630
- Testing
- Computed Tomography Perfusion Imaging
- Where
- United States
- Volunteers
- 1 people
- Sponsor
- ECOG-ACRIN Cancer Research Group
Carcinosarcoma, Ovarian
Paclitaxel/Carboplatin + Galunisertib for Patients With Carcinosarcoma of the Uterus or Ovary
This is a Phase 1 B feasibility trial with Galunsertib, a TGFβ inhibitor, in combination with carboplatin/paclitaxel in patients with newly diagnosed, persistent or recurrent carcinosarcoma of the uterus or ovary.
- Trial name
- NCT03206177
- Testing
- Galunisertib, Paclitaxel, Carboplatin
- Where
- United States
- Volunteers
- 26 people
- Sponsor
- University of Oklahoma
Female Sexual Dysfunction, Polycystic Ovary Syndrome
Evaluation of Vitamin D in Women With PCOS and Sexual Dysfunction
SUMMARY: Polycystic ovary syndrome (PCOS) is the most common endocrine disorder among reproductive age women with a prevalence as high as 15%.
- Trial name
- Vit-D/PCOS (NCT02865187)
- Testing
- Vitamin D, Hormonal contraception
- Where
- 2 sites in United States
- Volunteers
- 47 people
- Sponsor
- Wright State University
BRCA1 Mutation, BRCA2 Mutation
BrUOG 390: Neoadjuvant Treatment With Talazoparib
Ovarian cancer is the most fatal gynecologic cancer; in the US alone an estimated 22,000 women will be diagnosed in 2019, with over 13,000 dying of the disease.
- Conditions
- BRCA1 Mutation, BRCA2 Mutation, Ovarian Cancer, Fallopian Tube Cancer
- Trial name
- NCT04598321
- Testing
- Talazoparib Oral Capsule
- Where
- 2 sites in United States
- Volunteers
- 1 people
- Sponsor
- Brown University
Stage IIIC Fallopian Tube Cancer, Stage IIIC Ovarian Cancer
Hyperthermic Intraperitoneal Chemotherapy Trial Comparing Quality of Life in Patients With Stage IIIC-IV Ovarian, Fallopian Tube, or Primary Peritoneal Cancer
This phase II trial studies how well hyperthermic intraperitoneal chemotherapy works in improving quality of life in patients with stage IIIC-IV ovarian, fallopian tube, or primary peritoneal cancer.
- Conditions
- Stage IIIC Fallopian Tube Cancer, Stage IIIC Ovarian Cancer, Stage IIIC Primary Peritoneal Cancer, Stage IV Fallopian Tube Cancer
- Trial name
- NCT03188432
- Testing
- Carboplatin, Quality-of-Life Assessment, Questionnaire Administration
- Where
- United States
- Volunteers
- 50 people
- Sponsor
- Wake Forest University Health Sciences
Epithelial Ovarian Cancer
Ovarian Cancer Vaccine for Patients Who Have Progressed During the CAN-003 Study
The purpose of this trial is to assess the safety profile of Cvac for epithelial ovarian cancer patients who were enrolled in the Cvac clinical trial CAN-003 and are no longer eligible for study participation due to disease…
- Trial name
- CAN-003X (NCT01617629)
- Testing
- MUC1 Dendritic Cell Vaccine (Cvac)
- Where
- 6 sites in United States, Australia
- Volunteers
- 9 people
- Sponsor
- Prima BioMed Ltd
Ovarian Cancer, Fallopian Tube Cancer
Effectiveness of MORAb-003 in Women With Ovarian Cancer Who Have Relapsed After Platinum-Based Chemotherapy
The purpose of this study is to determine if an investigational drug called MORAb-003 is useful by itself or when used with other approved cancer drugs in treating women with ovarian cancer.
- Conditions
- Ovarian Cancer, Fallopian Tube Cancer, Peritoneal Neoplasms
- Trial name
- NCT00318370
- Testing
- Farletuzumab, Chemo Plus Far
- Where
- 20 sites in United States, Germany
- Volunteers
- 58 people
- Sponsor
- Morphotek
Ovarian Neoplasms
A Study of Niraparib Combined With Bevacizumab Maintenance Treatment in Participants With Advanced Ovarian Cancer Following Response on Front-Line Platinum-Based Chemotherapy
Niraparib is an oral inhibitor of poly adenosine diphosphate-ribose polymerase (PARP)-1 and PARP-2. This study will evaluate safety and efficacy of niraparib combined with bevacizumab as maintenance treatment in participants with…
- Trial name
- NCT03326193
- Testing
- Niraparib, Bevacizumab
- Where
- 29 sites in United States
- Volunteers
- 105 people
- Sponsor
- Tesaro, Inc.
Fallopian Tube Cancer, Ovarian Cancer
Ph II Atrasentan + DOXIL in Recurrent Ovarian/Fallopian/Peritoneal Serous Papillary Adenocarcinoma
RATIONALE: There is emerging data to suggest that the optimal use of angiogenesis inhibitors may be in combination with chemotherapy.
- Conditions
- Fallopian Tube Cancer, Ovarian Cancer, Peritoneal Cavity Cancer
- Trial name
- NCT00653328
- Testing
- atrasentan hydrochloride, doxil
- Where
- 6 sites in United States
- Volunteers
- 15 people
- Sponsor
- Vanderbilt-Ingram Cancer Center
Ovarian Cancer, Basal Cell Carcinoma
A Study of Vismodegib (GDC-0449) in Patients Treated With Vismodegib in a Previous Genentech-sponsored Phase I or II Cancer Study
This was a multicenter, open-label extension study. Patients who received vismodegib (GDC-0449) in a Genentech-sponsored study and who had completed the parent study or who continued to receive vismodegib at the time the parent…
- Conditions
- Ovarian Cancer, Basal Cell Carcinoma, Metastatic Colorectal Cancer
- Trial name
- NCT00959647
- Testing
- Vismodegib, FOLFOX, FOLFIRI
- Where
- 10 sites in United States
- Volunteers
- 19 people
- Sponsor
- Genentech, Inc.
Platinum-resistant Ovarian Cancer
Study With Afuresertib and Paclitaxel in Platinum Resistant Ovarian
Afuresertib is an AKT inhibitor, a new class of agents under development that may provide physicians with a new clinical option to control platinum resistant ovarian cancer (PROC) progression.
- Trial name
- PROFECTA-II (NCT04374630)
- Testing
- Paclitaxel, Afuresertib
- Where
- 47 sites in United States, China
- Volunteers
- 150 people
- Sponsor
- Laekna Limited
Cancer
Antithymocyte Globulin, Clofarabine, and Rituximab in Treating Patients After an Unsuccessful Stem Cell Transplant
RATIONALE: Antithymocyte globulin, clofarabine, and rituximab may stop the patient's immune system from rejecting the donor's stem cells when they do not exactly match the patient's blood.
- Trial name
- NCT00617929
- Testing
- anti-thymocyte globulin, rituximab, clofarabine
- Where
- United States
- Volunteers
- 12 people
- Sponsor
- Masonic Cancer Center, University of Minnesota
Fallopian Tube Cancer, Ovarian Cancer
Topotecan in Treating Patients With Recurrent Ovarian Epithelial, Fallopian Tube, or Primary Peritoneal Cancer
RATIONALE: Drugs used in chemotherapy, such as topotecan, work in different ways to stop the growth of tumor cells, either by killing the cells or by stopping them from dividing.
- Conditions
- Fallopian Tube Cancer, Ovarian Cancer, Primary Peritoneal Cavity Cancer
- Trial name
- NCT00114166
- Testing
- topotecan hydrochloride
- Where
- 78 sites in United States
- Volunteers
- 81 people
- Sponsor
- Gynecologic Oncology Group
Ovarian Cancer
Gleevec Study for Patients With Ovarian Cancer
Primary Objectives: 1. To determine the efficacy of Gleevec in patients with recurrent platinum-resistant, taxane-resistant epithelial ovarian cancer, primary peritoneal cancer, or fallopian tube cancer whose tumor expresses…
- Trial name
- NCT00510653
- Testing
- Imatinib Mesylate
- Where
- United States
- Volunteers
- 73 people
- Sponsor
- M.D. Anderson Cancer Center
Ovarian Cancer
Assessment of Efficacy of AZD2281 in Platinum Sensitive Relapsed Serous Ovarian Cancer
The primary purpose of this study to determine if AZD2281 is effective and well tolerated in maintaining the improvement in your cancer after previous platinum-based chemotherapy
- Trial name
- NCT00753545
- Testing
- AZD2281
- Where
- 107 sites in United States, Australia and 15 more
- Volunteers
- 265 people
- Sponsor
- AstraZeneca
Fallopian Tube Cancer, Ovarian Cancer
Sorafenib in Treating Patients With Ovarian Epithelial Cancer, Fallopian Tube Cancer, or Peritoneal Cancer in at Least the Second Remission
RATIONALE: Sorafenib may stop the growth of tumor cells by blocking some of the enzymes needed for cell growth and by blocking blood flow to the tumor.
- Conditions
- Fallopian Tube Cancer, Ovarian Cancer, Primary Peritoneal Cavity Cancer
- Trial name
- NCT00522301
- Testing
- sorafenib tosylate, immunoenzyme technique, immunohistochemistry staining method
- Where
- United States
- Volunteers
- 6 people
- Sponsor
- Memorial Sloan Kettering Cancer Center
Ovarian Carcinoma, Fallopian Tube Carcinoma
(PGA) for Platinum-resistant/Refractory, Paclitaxel-Pretreated Recurrent Ovarian and Peritoneal Carcinoma
To evaluate progression-free survival with two chemotherapy regimens on platinum-resistant/refractory ovarian and peritoneal carcinoma
- Conditions
- Ovarian Carcinoma, Fallopian Tube Carcinoma, Peritoneal Carcinoma
- Trial name
- PGA (NCT01936974)
- Testing
- Gemcitabine, Bevacizumab, Carboplatin
- Where
- United States
- Volunteers
- 7 people
- Sponsor
- Western Regional Medical Center
Peritoneal Carcinomatosis, Ovarian Cancer Stage IIIB
PIPAC Nab-pac for Stomach, Pancreas, Breast and Ovarian Cancer
The PIPAC nab-pac study is designed to examine the maximal tolerated dose of albumin bound nanoparticle paclitaxel (nab-pac, Abraxane) administered with repeated pressurized intraperitoneal aerosol chemotherapy (PIPAC), in a…
- Conditions
- Peritoneal Carcinomatosis, Ovarian Cancer Stage IIIB, Ovarian Cancer Stage IIIC, Ovarian Cancer Stage IV
- Trial name
- PIPAC-nabpac (NCT03304210)
- Testing
- PIPAC with Abraxane
- Where
- Belgium
- Volunteers
- 20 people
- Sponsor
- University Hospital, Ghent